ORIGINAL RESEARCH article
Front. Med.
Sec. Nephrology
This article is part of the Research TopicChallenges and Outcomes in Pediatric and Adult Kidney TransplantsView all 4 articles
The impact of living donor hypertension on later function of kidney graft in kidney transplantation
Provisionally accepted
Sophie Hügli1
David Jaques2Noemie Grouzmann2Theodore Pasquier2
Patricia Hirt-Minkowski3Solange Moll2Sophie De Seigneux2
Belen Ponte2*
Fadi Haidar2- 1Valais Romand Hospital Center, Sion, Switzerland
- 2Hopitaux Universitaires Geneve, Geneva, Switzerland
- 3Universitatsspital Basel, Basel, Switzerland
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
The impact of hypertension (HT) of living donors on later kidney graft function remains insufficiently understood. We retrospectively reviewed recipients of living donor (LD) kidney transplant (KTX) at a single tertiary center from January 2003 to December 2021 with a follow-up until December 2022. LD blood pressure (BP) values obtained with office measurement and 24h ambulatory BP monitoring (ABPM) were the main predictors, while recipient estimated glomerular filtration rate (eGFR) and proportion of kidney fibrosis on biopsies were the outcomes. Multivariate analyses were adjusted for pre-transplant donor characteristics: age, sex, ethnicity, body mass index (BMI and eGFR. 212 LD KTX recipients were included, with mean age 51 years. 133 were women (62.7%). 73 (34.4%) LD were hypertensive based on office BP. In a sub-group of 112 LD with ABPM, 64 (57.1%) were hypertensive. Office systolic blood pressure (SBP) was negatively associated with eGFR at 6 months, 1 year, 5 years and 10 years (p<0.05). Office SBP was positively associated with kidney fibrosis at 1 year (p<0.05). Those associations were not significant after multivariate adjustment. In conclusion, while an adverse impact of LD HT on later kidney function and fibrosis was measured, this effect seemed negligible after accounting for other more relevant clinical characteristics.
Keywords: Living donor, Kidney transplant, Hypertension, EGFR, Fibrosis
Received: 15 Aug 2025; Accepted: 17 Nov 2025.
Copyright: © 2025 Hügli, Jaques, Grouzmann, Pasquier, Hirt-Minkowski, Moll, De Seigneux, Ponte and Haidar. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Belen Ponte, belen.ponte@hug.ch
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.